AI-enabled fundoscopy · Made for Africa

The answer is often in the eyes.

AEyeCARE puts specialist-level retinal screening in the hands of nurses, technicians and community health workers. A photo of the eye, read by AI in under a minute, at the bedside, with no internet needed.

A retinal photograph showing the white patches and haemorrhages of malarial retinopathy
Retinopathy detected

The problem

A child in a coma. Is it malaria, or something else?

Cerebral malaria is the deadliest form of malaria, and it is easy to get wrong. In a landmark autopsy study, about 1 in 4 children diagnosed with cerebral malaria had died of something else, such as meningitis or sepsis, that might have been treated.

The retina is wired to the brain. When malaria damages the brain's small blood vessels, it leaves the same marks in the eye, and they can be seen. The World Health Organization notes that a missing eye examination is one reason cerebral malaria is misdiagnosed.

But Nigeria has fewer than 1,000 eye specialists for more than 200 million people. So the eye is almost never examined.

A health worker uses a handheld retinal camera on a child in a hospital bed

Our product

ASPIRE™

Autodetection Software for Plasmodium Infection in Retinal Exams

A handheld retinal camera with an Android phone showing a retinal image
  1. 01

    Photograph the eye

    A handheld retinal camera and an Android phone. One short training session is enough for nurses and technicians.

  2. 02

    AI reads the image on the device

    Trained on about 100,000 retinal images. It runs offline, so it works on the ward, in the clinic and in the community.

  3. 03

    A result in under a minute

    Retinopathy detected, or not detected. A positive result supports a diagnosis of cerebral malaria. A negative one says: keep treating, and keep looking for other causes.

ASPIRE is a guide, not a judge. It supports the health worker's decision; it does not replace clinical judgement.

The evidence

A promise is not proof. So we tested it.

A prospective, multicentre trial from 2022 to 2024 compared ASPIRE with a panel of three eye specialists, in children in a coma.

834children in a coma
12hospitals
87%sensitivity (95% CI 83–90)
85%specificity (95% CI 81–88)

Both pre-set goals were met. Trial registration NCT06915285. Next, we have to show that faster, better diagnosis changes outcomes, and that study is our priority.

Our focus

One picture of the eye. Many diseases.

The retina shows what is happening in the body's small blood vessels. We are building screening for the conditions that cost African lives and sight.

  • Validated · pilots in Nigeria

    Malarial retinopathy

    A critical marker of cerebral malaria. Fast bedside screening in children's emergency units.

  • Validation under way

    Diabetic retinopathy

    A major cause of blindness in diabetes. Clinical validation is running across 16 centres in Nigeria.

  • Study launching

    Hypertensive retinopathy

    About 1 in 3 Nigerian adults has high blood pressure. The retina can show its damage early.

  • Exploratory

    Pregnancy and pre-eclampsia

    Early warning of hypertensive disorders of pregnancy, to protect mothers and babies.

Our story

From a research ward in Malawi to hospitals in Nigeria

ASPIRE began with research in Malawi in 2016, funded by the US National Institutes of Health, where clinical data collection started. It then grew across several African countries into a tested product.

AEyeCARE was formed to take it to the health workers who need it, starting in Nigeria.

Co-founder & CEO

Dr Folajimi Adebowale

Physician, health strategist and documentary filmmaker. MBBS, MBA.

Co-founder

Dr Vinayak Joshi

Biomedical scientist, PhD.

Get in touch

Put screening where the patients are.

Hospitals, states, funders and partners: we would like to hear from you.

Emailhello@aeyecare.co Phone+234 803 538 5677

Office24B Bashorun Okunsanya, Lekki Phase 1, Lagos